RESUMO
The efficacy of the combination therapy with two antidepressants from different pharmacological families in patients with treatment-resistant depression has been reported in multiple studies. In this prospective 12-weeks open-label study, we assessed the effectiveness of the addition of reboxetine to 79 depressive outpatients diagnosed with major depressive disorder (MDD) according to the DSM-IV criteria who had previously not responded, or had done so only in a partial way, over 8 weeks of conventional treatment, in monotherapy, with duloxetine. Efficacy was assessed using the 21-item Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression-Improvement (CGI-I). Safety was evaluated by recording spontaneously reported adverse events. Data were analysed on an intent-to-treat basis, using the last-observation-carried-forward method. Mean HDRS reduction was 65.5% (P < 0.0001). The percentages of responders (>or=50% reduction in HDRS) and patients considered benefiting from complete remission (HDRS Assuntos
Antidepressivos/uso terapêutico
, Transtorno Depressivo Maior/tratamento farmacológico
, Morfolinas/uso terapêutico
, Tiofenos/uso terapêutico
, Adolescente
, Inibidores da Captação Adrenérgica/efeitos adversos
, Inibidores da Captação Adrenérgica/farmacologia
, Inibidores da Captação Adrenérgica/uso terapêutico
, Adulto
, Idoso
, Antidepressivos/efeitos adversos
, Resistência a Medicamentos
, Quimioterapia Combinada
, Cloridrato de Duloxetina
, Feminino
, Humanos
, Masculino
, Pessoa de Meia-Idade
, Morfolinas/efeitos adversos
, Escalas de Graduação Psiquiátrica
, Reboxetina
, Inibidores Seletivos de Recaptação de Serotonina/efeitos adversos
, Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico
, Tiofenos/efeitos adversos
, Fatores de Tempo
, Resultado do Tratamento
, Adulto Jovem